---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-041613"
form_type: "8-K"
ticker: "STAA"
cik: "0000718937"
company_name: "STAAR SURGICAL CO"
filed_at: "2024-04-04T23:59:59+00:00"
generated_at: "2026-06-04T02:37:01.782058+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "medium"
source: SEC EDGAR
---

# STAAR Surgical preliminary Q1 net sales >$77M; record US ICL sales of $5M, up 20% sequentially

## Summary
- Preliminary Q1 2024 net sales in excess of $77M; US ICL sales hit record $5M, up ~20% sequentially.
- EMEA ICL sales up ~11% YoY; APAC ICL sales up ~9% including ~10% growth in China.
- Cash and investments ~$248M (Dec 2023: $232.4M); accounts receivable ~$70M (Dec 2023: $94.7M).
- Fiscal 2024 net sales outlook now expected at higher end of $335M-$340M range.
- Full Q1 results and 2024 outlook to be discussed on earnings call on/about May 8, 2024.

## SEC filing metadata
- accession: 0000950170-24-041613
- form_type: 8-K
- ticker: STAA
- cik: 0000718937
- company_name: STAAR SURGICAL CO
- filed_at: 2024-04-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/718937/000095017024041613/0000950170-24-041613-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/718937/000095017024041613/staa-20240404.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-041613
- JSON: https://secwatch.observer/filing/0000950170-24-041613.json
- Plain text: https://secwatch.observer/filing/0000950170-24-041613.txt

## Key facts
- Earnings Releases
  STAAR SURGICAL CO reported first quarter ended March 29, 2024 results: revenue in excess of $77 million.
  - Period: first quarter ended March 29, 2024
  - Revenue: in excess of $77 million
  - Result: preliminary results
  source text: STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICLTM) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million, with U.S. ICL sales expected to be $5 million for the quarter.
  evidence_url: https://www.sec.gov/Archives/edgar/data/718937/000095017024041613/0000950170-24-041613-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.